Government-Owned Inventions; Availability for Licensing, 15596 [2024-04424]
Download as PDF
<![CDATA[
15596
Federal Register / Vol. 89, No. 43 / Monday, March 4, 2024 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Benjamin Hurley at 240–276–5489 or
benjamin.hurley@nih.gov. Licensing
information may be obtained by
communicating with the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852: tel. 301–496–
2644. A signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished information
related to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
Vaccinia Virus Strain WR With
Deletion of Growth Factor Genes
(‘‘vSC20’’)
Description of Technology:
This technology relates to mutant
vaccinia virus expression vectors.
Researchers at NIAID have developed a
recombinant vaccinia virus in which the
growth factor genes were deleted from
both ends of the genome. The
recombinant vaccinia virus is attenuated
and can replicate efficiently in rapidly
dividing cells such as tumors.
The mutation in the recombinant
virus was confirmed through various
tests, including Southern blot analysis
and growth factor assays. The mutant
expression vectors show diminished
virus replication in non-dividing cells
and attenuation in animal models
compared to other vaccinia virus
expression vectors. They may have use
as vaccines, cancer therapies as well as
for gene delivery.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
VerDate Sep<11>2014
17:45 Mar 01, 2024
Jkt 262001
Potential Commercial Applications:
• Recombinant vaccinia virus with
deletion of growth factor genes can be
used for cancer therapeutics and
diagnostics.
Competitive Advantages:
• The recombinant vaccinia virus is
attenuated and can replicate efficiently
in rapidly dividing cells, such as
tumors.
• Applications include use in tumordirected gene therapy, given the
enhanced safety profile, tumor
selectivity, and the oncolytic effects
after systemic delivery.
Development Stage:
• Pre-Clinical.
Inventors: Bernard Moss, M.D., Ph.D.
and Sekhar Chakrabarti, Ph.D., both of
NIAID.
Publications: Buller, R M et al.
‘‘Deletion of the vaccinia virus growth
factor gene reduces virus virulence.’’
Journal of virology vol. 62,3 (1988): 866–
74. doi:10.1128/JVI.62.3.866–874.1988;
McCart, J A et al. ‘‘Systemic cancer
therapy with a tumor-selective vaccinia
virus mutant lacking thymidine kinase
and vaccinia growth factor genes.’’
Cancer research vol. 61,24 (2001): 8751–
7.
Intellectual Property: HHS Reference
No. E–028–2021. U.S. Patent
8506947B2, issued on August 13, 2013.
Licensing Contact: To license this
technology, please contact Benjamin
Hurley at 240–276–5489 or benjamin.
hurley@nih.gov and reference E–028–
2021.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this technology. For
collaboration opportunities, please
contact Benjamin Hurley at 240–276–
5489 or benjamin.hurley@nih.gov.
Dated: February 14, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2024–04424 Filed 3–1–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
PO 00000
Notice.
Frm 00056
Fmt 4703
Sfmt 4703
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Peter Tung at 240–669–5483 or peter.
tung@nih.gov. Licensing information
may be obtained by communicating
with the Technology Transfer and
Intellectual Property Office, National
Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, Rockville,
MD 20852: tel. 301–496–2644. A signed
Confidential Disclosure Agreement will
be required to receive copies of
unpublished information related to the
invention.
Licensing information and copies of
the patent applications listed below may
be obtained by communicating with the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852 by
contacting Peter Tung at 240–669–5483
or peter.tung@nih.gov. A signed
Confidential Disclosure Agreement will
be required to receive copies of
unpublished patent applications related
to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
SUMMARY:
Enhanced Single-Component AMA1–
RON2 Vaccine Candidates: A
Breakthrough in Malaria Immunization
Description of Technology
This technology focuses on the
creation of single-component AMA1–
RON2 (Apical membrane antigen 1rhoptry neck protein 2) vaccine
candidates. These candidates are based
on a novel composition of matter
designed to elicit a more effective
immune response against the malaria
parasite Plasmodium falciparum. The
standout aspect of this technology is the
Structure-Based Design 1 (SBD1)
immunogen, engineered through a
structure-based design that significantly
enhances its ability to produce potent,
strain-transcending neutralizing
antibodies. This approach not only
surpasses the efficacy of traditional
AMA1–RON2 complexes and other
insertion fusion designs but also boasts
higher thermal stability, indicating
better preservation and longevity of the
vaccine. The technology’s increased
stability and efficiency in production
present an opportunity to lower vaccine
E:\FR\FM\04MRN1.SGM
04MRN1
]]>Agencies
[Federal Register Volume 89, Number 43 (Monday, March 4, 2024)]
[Notices]
[Page 15596]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-04424]
[[Page 15596]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Benjamin Hurley at 240-276-5489 or
[email protected]. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Vaccinia Virus Strain WR With Deletion of Growth Factor Genes
(``vSC20'')
Description of Technology:
This technology relates to mutant vaccinia virus expression
vectors. Researchers at NIAID have developed a recombinant vaccinia
virus in which the growth factor genes were deleted from both ends of
the genome. The recombinant vaccinia virus is attenuated and can
replicate efficiently in rapidly dividing cells such as tumors.
The mutation in the recombinant virus was confirmed through various
tests, including Southern blot analysis and growth factor assays. The
mutant expression vectors show diminished virus replication in non-
dividing cells and attenuation in animal models compared to other
vaccinia virus expression vectors. They may have use as vaccines,
cancer therapies as well as for gene delivery.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
Recombinant vaccinia virus with deletion of growth factor
genes can be used for cancer therapeutics and diagnostics.
Competitive Advantages:
The recombinant vaccinia virus is attenuated and can
replicate efficiently in rapidly dividing cells, such as tumors.
Applications include use in tumor-directed gene therapy,
given the enhanced safety profile, tumor selectivity, and the oncolytic
effects after systemic delivery.
Development Stage:
Pre-Clinical.
Inventors: Bernard Moss, M.D., Ph.D. and Sekhar Chakrabarti, Ph.D.,
both of NIAID.
Publications: Buller, R M et al. ``Deletion of the vaccinia virus
growth factor gene reduces virus virulence.'' Journal of virology vol.
62,3 (1988): 866-74. doi:10.1128/JVI.62.3.866-874.1988; McCart, J A et
al. ``Systemic cancer therapy with a tumor-selective vaccinia virus
mutant lacking thymidine kinase and vaccinia growth factor genes.''
Cancer research vol. 61,24 (2001): 8751-7.
Intellectual Property: HHS Reference No. E-028-2021. U.S. Patent
8506947B2, issued on August 13, 2013.
Licensing Contact: To license this technology, please contact
Benjamin Hurley at 240-276-5489 or [email protected] and
reference E-028-2021.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Benjamin Hurley at 240-276-5489 or
[email protected].
Dated: February 14, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-04424 Filed 3-1-24; 8:45 am]
BILLING CODE 4140-01-P
